Agent for the therapy of factor viii-resistant hemophilia a, and a process for the preparation thereof

Abstract From the Canadian patent

Ma 574, Dr. Ha/Bi, Abstract of the disclosure: An agent for the therapy of hemophilia A which is resistant to treatment with factor VIII is described and is, obtainable by maintaining a mixture of factor VIII antithrombin III, a phospholipid and calcium ions in an aqueous solution at a temperature of from 1 to 45°C for at least one minute, adding factor IX, and maintaining the solution at a temperature of from 1 to 45°C until addition of a sample of this solution to an inhibitor plasma results in a partial thromboplastin time (PTT) of 15 to 30 seconds, where appropriate adding a polyol and, where appropriate, an amino acid, and where appro-, priate, drying the solution.